SYNCOPE

The overall goal of the project is to test if early systemic control and precision-targeted selection to adjuvant chemotherapy, as a comprehensive treatment strategy, would reduce the rate of systemic recurrence in mrEMVI+ without increasing the harms from adverse effects. The specific research questions are:

1. Is application of systemic control with precision approach over the course of the rectal cancer therapy logistically feasible?
2. Does systemic control and precision approach as a treatment strategy improve recurrence-free survival of rectal cancer patients?.
3. Is circulating tumor DNA a reliable postoperative biomarker of minimal residual disease (MRD) for adjuvant chemotherapy decisions?
4. Does chemosensitivity of patient-derived organoids (PDO) correlates to therapy response in a prospective setting?

• Duration: [Add duration]
• Role: [Add role]